Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 344

1.

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.

Cohen JA, Trojano M, Mowry EM, Uitdehaag BM, Reingold SC, Marrie RA.

Mult Scler. 2019 Nov 28:1352458519892555. doi: 10.1177/1352458519892555. [Epub ahead of print]

PMID:
31778094
2.

Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.

van Munster CEP, Kaya L, Lam KH, Kalkers NF, Killestein J, Uitdehaag BMJ.

Mult Scler Relat Disord. 2019 Nov 5;38:101489. doi: 10.1016/j.msard.2019.101489. [Epub ahead of print]

PMID:
31731213
3.

Patients' expectations of autologous hematopoietic stem cell transplantation as a treatment for MS.

De Kleermaeker FGCM, Uitdehaag BMJ, van Oosten BW.

Mult Scler Relat Disord. 2019 Oct 24;37:101467. doi: 10.1016/j.msard.2019.101467. [Epub ahead of print]

PMID:
31678857
4.

Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.

Goldman MD, LaRocca NG, Rudick RA, Hudson LD, Chin PS, Francis GS, Jacobs A, Kapoor R, Matthews PM, Mowry EM, Balcer LJ, Panzara M, Phillips G, Uitdehaag BMJ, Cohen JA; Multiple Sclerosis Outcome Assessments Consortium.

Neurology. 2019 Nov 19;93(21):e1921-e1931. doi: 10.1212/WNL.0000000000008519. Epub 2019 Oct 22.

PMID:
31641014
5.

Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis.

Eijlers AJC, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, Pouwels PJW, Uitdehaag BMJ, Barkhof F, Vrenken H, Schoonheim MM, Geurts JJG.

Neurology. 2019 Oct 1;93(14):e1348-e1359. doi: 10.1212/WNL.0000000000008198. Epub 2019 Sep 4.

PMID:
31484713
6.

Validation of mean upper cervical cord area (MUCCA) measurement techniques in multiple sclerosis (MS): High reproducibility and robustness to lesions, but large software and scanner effects.

Weeda MM, Middelkoop SM, Steenwijk MD, Daams M, Amiri H, Brouwer I, Killestein J, Uitdehaag BMJ, Dekker I, Lukas C, Bellenberg B, Barkhof F, Pouwels PJW, Vrenken H.

Neuroimage Clin. 2019 Aug 6;24:101962. doi: 10.1016/j.nicl.2019.101962. [Epub ahead of print]

7.

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?

Dekker I, Sombekke MH, Balk LJ, Moraal B, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2019 Aug 2:1352458519864933. doi: 10.1177/1352458519864933. [Epub ahead of print]

PMID:
31373535
8.

Objective quantification of vitreous haze on optical coherence tomography scans: no evidence for relationship between uveitis and inflammation in multiple sclerosis.

Coric D, Ometto G, Montesano G, Keane PA, Balk LJ, Uitdehaag BMJ, Petzold A, Crabb DP, Denniston AK.

Eur J Neurol. 2019 Jul 25. doi: 10.1111/ene.14048. [Epub ahead of print]

PMID:
31342606
9.

Infusion-related events during natalizumab: No need for post-infusion monitoring.

Loonstra FC, van Rossum JA, van Kempen ZL, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2019 Jun 25:1352458519860415. doi: 10.1177/1352458519860415. [Epub ahead of print]

PMID:
31237826
10.

Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.

Loonstra FC, Verberk IMW, Wijburg MT, Wattjes MP, Teunissen CE, van Oosten BW, Uitdehaag BMJ, Killestein J, van Kempen ZLE.

Ann Neurol. 2019 Aug;86(2):322-324. doi: 10.1002/ana.25523. Epub 2019 Jun 26. No abstract available.

PMID:
31192473
11.

Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.

Dekker I, Leurs CE, Hagens MHJ, van Kempen ZLE, Kleerekooper I, Lissenberg-Witte BI, Barkhof F, Uitdehaag BMJ, Balk LJ, Wattjes MP, Killestein J.

Mult Scler Relat Disord. 2019 Aug;33:82-87. doi: 10.1016/j.msard.2019.05.017. Epub 2019 May 28.

PMID:
31174043
12.

Saccadic fatigability in the oculomotor system.

Nij Bijvank JA, van Rijn LJ, Kamminga M, Tan HS, Uitdehaag BMJ, Petzold A, Balk LJ.

J Neurol Sci. 2019 Jul 15;402:167-174. doi: 10.1016/j.jns.2019.05.024. Epub 2019 May 23.

PMID:
31154074
13.

Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.

Nij Bijvank JA, van Rijn LJ, Balk LJ, Tan HS, Uitdehaag BMJ, Petzold A.

Neurology. 2019 May 14;92(20):e2299-e2308. doi: 10.1212/WNL.0000000000007499. Epub 2019 Apr 19.

14.

Quantification of Visual Fixation in Multiple Sclerosis.

Nij Bijvank JA, Petzold A, Coric D, Tan HS, Uitdehaag BMJ, Balk LJ, van Rijn LJ.

Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1372-1383. doi: 10.1167/iovs.18-26096. Erratum in: Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2571.

PMID:
30938772
15.

High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate.

Doesburg D, Vennegoor A, Uitdehaag BMJ, van Oosten BW.

Mult Scler Relat Disord. 2019 Jun;31:32-37. doi: 10.1016/j.msard.2019.03.011. Epub 2019 Mar 16.

PMID:
30901702
16.

Evaluation of the content coverage of questionnaires containing basic and instrumental activities of daily living (ADL) used in adult patients with brain tumors.

Oort Q, Taphoorn MJB, Sikkes SAM, Uitdehaag BMJ, Reijneveld JC, Dirven L.

J Neurooncol. 2019 May;143(1):1-13. doi: 10.1007/s11060-019-03136-9. Epub 2019 Mar 18.

17.

Setwise comparison: efficient fine-grained rating of movement videos using algorithmic support - a proof of concept study.

Steinheimer S, Dorn JF, Morrison C, Sarkar A, D'Souza M, Boisvert J, Bedi R, Burggraaff J, Kontschieder P, Dahlke F, Sellen A, Uitdehaag BMJ, Kappos L, Kamm CP.

Disabil Rehabil. 2019 Feb 20:1-7. doi: 10.1080/09638288.2018.1563832. [Epub ahead of print]

PMID:
30782055
18.

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.

Kanhai KMS, Nij Bijvank JA, Wagenaar YL, Klaassen ES, Lim K, Bergheanu SC, Petzold A, Verma A, Hesterman J, Wattjes MP, Uitdehaag BMJ, van Rijn LJ, Groeneveld GJ.

CNS Neurosci Ther. 2019 Jun;25(6):697-703. doi: 10.1111/cns.13096. Epub 2019 Feb 12.

19.

[Paroxysmal hypothermia in multiple sclerosis].

De Kleermaeker FGCM, Uitdehaag BMJ, van Oosten BW, van Munster CEP.

Ned Tijdschr Geneeskd. 2019 Jan 14;163. pii: D3116. Dutch.

PMID:
30676705
20.

Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).

van Munster CE, Kaya L, Obura M, Kalkers NF, Uitdehaag BM.

Mult Scler. 2019 Jan 18:1352458518823489. doi: 10.1177/1352458518823489. [Epub ahead of print]

PMID:
30657002
21.

Predicting clinical progression in multiple sclerosis after 6 and 12 years.

Dekker I, Eijlers AJC, Popescu V, Balk LJ, Vrenken H, Wattjes MP, Uitdehaag BMJ, Killestein J, Geurts JJG, Barkhof F, Schoonheim MM.

Eur J Neurol. 2019 Jun;26(6):893-902. doi: 10.1111/ene.13904. Epub 2019 Feb 2.

22.

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.

Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, Kappos L, Derfuss T.

JAMA Neurol. 2019 Mar 1;76(3):274-281. doi: 10.1001/jamaneurol.2018.4239.

PMID:
30615019
23.

Acid sphingomyelinase: No potential as a biomarker for multiple sclerosis.

Leurs CE, Lopes Pinheiro MA, Wierts L, den Hoedt S, Mulder MT, Eijlers AJC, Schoonheim MM, Balk LJ, Uitdehaag BMJ, Killestein J, de Vries HE.

Mult Scler Relat Disord. 2019 Feb;28:44-49. doi: 10.1016/j.msard.2018.11.024. Epub 2018 Nov 30.

PMID:
30553168
24.

Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS.

Schoonhoven DN, Fraschini M, Tewarie P, Uitdehaag BM, Eijlers AJ, Geurts JJ, Hillebrand A, Schoonheim MM, Stam CJ, Strijbis EM.

Mult Scler. 2019 Dec;25(14):1896-1906. doi: 10.1177/1352458518810260. Epub 2018 Nov 22.

PMID:
30465461
25.

Development of the Arm Function in Multiple Sclerosis Questionnaire-Short Form (AMSQ-SF): A static 10-item version.

Luijten MA, Eekhout I, D'Hooghe M, Uitdehaag BM, Mokkink LB.

Mult Scler. 2018 Nov 9:1352458518808197. doi: 10.1177/1352458518808197. [Epub ahead of print]

26.

Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.

Eijlers AJC, van Geest Q, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, Barkhof F, Uitdehaag BMJ, Schoonheim MM, Geurts JJG.

Brain. 2018 Sep 1;141(9):2605-2618. doi: 10.1093/brain/awy202.

PMID:
30169585
27.

Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.

van Munster CE, D'Souza M, Steinheimer S, Kamm CP, Burggraaff J, Diederich M, Kravalis K, Dorn J, Walsh L, Dahlke F, Kappos L, Uitdehaag BM.

Mult Scler. 2019 Oct;25(12):1673-1681. doi: 10.1177/1352458518796690. Epub 2018 Aug 31.

28.

Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis.

D'Souza M, Steinheimer S, Dorn J, Morrison C, Boisvert J, Kravalis K, Burggraaff J, van Munster CE, Diederich M, Sellen A, Kamm CP, Dahlke F, Uitdehaag BM, Kappos L.

Mult Scler J Exp Transl Clin. 2018 Aug 9;4(3):2055217318792399. doi: 10.1177/2055217318792399. eCollection 2018 Jul-Sep.

29.

Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.

Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):44-46. doi: 10.1136/jnnp-2018-318261. Epub 2018 Aug 12.

PMID:
30100552
30.

Natural History of Vanishing White Matter.

Hamilton EMC, van der Lei HDW, Vermeulen G, Gerver JAM, Lourenço CM, Naidu S, Mierzewska H, Gemke RJBJ, de Vet HCW, Uitdehaag BMJ, Lissenberg-Witte BI; VWM Research Group, van der Knaap MS.

Ann Neurol. 2018 Aug;84(2):274-288. doi: 10.1002/ana.25287. Epub 2018 Sep 6.

31.

A standardized protocol for quantification of saccadic eye movements: DEMoNS.

Nij Bijvank JA, Petzold A, Balk LJ, Tan HS, Uitdehaag BMJ, Theodorou M, van Rijn LJ.

PLoS One. 2018 Jul 16;13(7):e0200695. doi: 10.1371/journal.pone.0200695. eCollection 2018.

32.

Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis.

Uitdehaag BMJ.

CNS Drugs. 2018 Jun;32(6):543-558. doi: 10.1007/s40263-018-0530-8. Review.

33.

Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.

Piena MA, Heisen M, Wormhoudt LW, Wingerden JV, Frequin STFM, Uitdehaag BMJ.

J Med Econ. 2018 Oct;21(10):968-976. doi: 10.1080/13696998.2018.1489255. Epub 2018 Jul 9.

PMID:
29911917
34.

The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.

Nauta IM, Balk LJ, Sonder JM, Hulst HE, Uitdehaag BM, Fasotti L, de Jong BA.

Mult Scler. 2019 Oct;25(11):1543-1546. doi: 10.1177/1352458518777295. Epub 2018 May 18.

35.

Fronto-limbic disconnection in patients with multiple sclerosis and depression.

van Geest Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, Pouwels PJ, Twisk JW, Smit JH, Uitdehaag BM, Geurts JJ, van Oppen P, Hulst HE.

Mult Scler. 2019 Apr;25(5):715-726. doi: 10.1177/1352458518767051. Epub 2018 Mar 28.

36.

Software updates of OCT segmentation algorithms influence longitudinal assessment of retinal atrophy.

Coric D, Petzold A, Uitdehaag BMJ, Balk LJ.

J Neurol Sci. 2018 Apr 15;387:16-20. doi: 10.1016/j.jns.2018.01.020. Epub 2018 Feb 3.

PMID:
29571856
37.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

38.

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.

JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.

39.

The role of the cerebellum in multiple sclerosis-150 years after Charcot.

Parmar K, Stadelmann C, Rocca MA, Langdon D, D'Angelo E, D'Souza M, Burggraaff J, Wegner C, Sastre-Garriga J, Barrantes-Freer A, Dorn J, Uitdehaag BMJ, Montalban X, Wuerfel J, Enzinger C, Rovira A, Tintore M, Filippi M, Kappos L, Sprenger T; MAGNIMS study group.

Neurosci Biobehav Rev. 2018 Jun;89:85-98. doi: 10.1016/j.neubiorev.2018.02.012. Epub 2018 Feb 23. Review.

PMID:
29477616
40.

Explaining the heterogeneity of functional connectivity findings in multiple sclerosis: An empirically informed modeling study.

Tewarie P, Steenwijk MD, Brookes MJ, Uitdehaag BMJ, Geurts JJG, Stam CJ, Schoonheim MM.

Hum Brain Mapp. 2018 Jun;39(6):2541-2548. doi: 10.1002/hbm.24020. Epub 2018 Feb 21.

41.

Anxiety is more important than depression in MS - Commentary.

de Jong BA, Uitdehaag BM.

Mult Scler. 2018 Apr;24(4):444-445. doi: 10.1177/1352458518756516. Epub 2018 Jan 30. No abstract available.

42.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

43.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
44.

Does the presence of multiple sclerosis impact on symptom profile in depressed patients?

Boeschoten RE, Schaakxs R, Dekker J, Uitdehaag BMJ, Beekman ATF, Smit JH, Penninx BWJH, van Oppen P.

J Psychosom Res. 2017 Dec;103:70-76. doi: 10.1016/j.jpsychores.2017.10.006. Epub 2017 Oct 12.

PMID:
29167049
45.

Cognitive rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial.

Nauta IM, Speckens AEM, Kessels RPC, Geurts JJG, de Groot V, Uitdehaag BMJ, Fasotti L, de Jong BA.

BMC Neurol. 2017 Nov 21;17(1):201. doi: 10.1186/s12883-017-0979-y.

46.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J; Dutch-Belgian Natalizumab-Associated PML Study Group.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):535-541. doi: 10.1136/jnnp-2017-316886. Epub 2017 Nov 15.

PMID:
29142146
47.

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.

Dekker I, Sombekke MH, Witte BI, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2018 Apr;24(4):481-490. doi: 10.1177/1352458517736147. Epub 2017 Nov 6. Erratum in: Mult Scler. 2019 Jan;25(1):NP2.

48.

The Arm Function in Multiple Sclerosis Questionnaire was successfully translated to German.

Steinheimer S, Wendel M, Vanbellingen T, Westers LT, Hodak J, Blatter V, Uitdehaag BMJ, Kamm CP.

J Hand Ther. 2018 Jan - Mar;31(1):137-140.e1. doi: 10.1016/j.jht.2017.09.010. No abstract available.

PMID:
29102479
49.

Structure-function relationships in the visual system in multiple sclerosis: an MEG and OCT study.

Tewarie P, Balk LJ, Hillebrand A, Steenwijk MD, Uitdehaag BMJ, Stam CJ, Petzold A.

Ann Clin Transl Neurol. 2017 Jul 25;4(9):614-621. doi: 10.1002/acn3.415. eCollection 2017 Sep.

50.

Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis.

Coric D, Balk LJ, Uitdehaag BMJ, Petzold A.

Eur J Neurol. 2017 Dec;24(12):1479-1484. doi: 10.1111/ene.13443. Epub 2017 Oct 9.

PMID:
28887838

Supplemental Content

Loading ...
Support Center